Open access
Open access
Powered by Google Translator Translator

Oncology – Gastrointestinal

Review | Cholangiocarcinoma — novel biological insights and therapeutic strategies

22 May, 2023 | 13:38h | UTC

Cholangiocarcinoma — novel biological insights and therapeutic strategies – Nature Reviews Clinical Oncology

 

Commentary on Twitter

 

Review | Hereditary colorectal, gastric, and pancreatic cancer

18 May, 2023 | 13:43h | UTC

Hereditary colorectal, gastric, and pancreatic cancer: comprehensive review – BJS Open

 

Commentary on Twitter

 

Current perioperative care in pancreatoduodenectomy: a step-by-step surgical roadmap from first visit to discharge

16 May, 2023 | 14:52h | UTC

Current Perioperative Care in Pancreatoduodenectomy: A Step-by-Step Surgical Roadmap from First Visit to Discharge – Cancers

 

Commentary on Twitter

 

An update on the role of immunohistochemistry in the evaluation of pancreatic/liver/gastrointestinal luminal tract disorders

15 May, 2023 | 13:02h | UTC

An Update on the Role of Immunohistochemistry in the Evaluation of Pancreatic/Liver/Gastrointestinal Luminal Tract Disorders – Archives of Pathology & Laboratory Medicine

 

2023 Rectal cancer lexicon update | Revised consensus on terminology and staging

15 May, 2023 | 12:50h | UTC

Rectal cancer lexicon 2023 revised and updated consensus statement from the Society of Abdominal Radiology Colorectal and Anal Cancer Disease-Focused Panel – Abdominal Radiology

 

EASL-ILCA Clinical practice guidelines on the management of intrahepatic cholangiocarcinoma

9 May, 2023 | 14:47h | UTC

EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma – Journal of Hepatology

 

Commentary on Twitter

 

RCT | Tislelizumab plus chemotherapy vs placebo plus chemotherapy for advanced esophageal squamous cell carcinoma

8 May, 2023 | 13:04h | UTC

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 

RCT | Adding Bevacizumab to trifluridine–tipiracil enhances overall survival in refractory metastatic colorectal cancer

5 May, 2023 | 15:13h | UTC

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 

RCT | Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colon cancer

2 May, 2023 | 13:36h | UTC

Efficacy and Safety of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer: A Phase 3 Randomized Clinical Trial – JAMA Surgery (free for a limited period)

Invited Commentary: Heated Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer–Restarting the Fire – JAMA Surgery (free for a limited period)

 

Commentary on Twitter

 

Review | Multidisciplinary management in the treatment of intrahepatic cholangiocarcinoma

28 Apr, 2023 | 13:03h | UTC

Multidisciplinary management in the treatment of intrahepatic cholangiocarcinoma – CA: A Cancer Journal for Clinicians

 

M-A | Immune checkpoint inhibitors vs. chemotherapy in the 2nd-line treatment of advanced esophageal squamous cell carcinoma

28 Apr, 2023 | 12:56h | UTC

Efficacy and safety of immune checkpoint inhibitors versus chemotherapy in the second-line treatment of advanced esophageal squamous cell carcinoma: a meta-analysis and systematic review – Journal of Thoracic Disease

 

RCT | Intraperitoneal carboplatin achieves modest PFS gains in advanced ovarian cancer

25 Apr, 2023 | 14:24h | UTC

Intraperitoneal Carboplatin for Ovarian Cancer — A Phase 2/3 Trial – NEJM Evidence

 

Commentary on Twitter

 

RCT | Panitumumab vs. Bevacizumab added to 1st-line chemo in RAS wild-type left-sided metastatic colorectal cancer

24 Apr, 2023 | 13:41h | UTC

Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Anti-EGFR Therapy for Left-Sided RAS Wild-type Colorectal Cancer—PARADIGM Shift – JAMA Oncology (free for a limited period)

 

Commentary on Twitter

 

Cohort Study | Circulating tumor DNA methylation may enable early detection of recurrence in colorectal cancer

24 Apr, 2023 | 13:12h | UTC

Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation – JAMA Oncology (free for a limited period)

Editorial: Liquid Biopsy Assessment of Molecular Residual Disease in Localized Colorectal Cancer: Is It Ready for Prime Time? – JAMA Oncology (free for a limited period)

Related: Study shows patients with circulating tumor DNA are at increased risk of relapse after surgery for resectable colorectal cancer

Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices – Journal of Clinical Oncology

 

Commentary on Twitter

 

RCT | Small benefit from pembrolizumab + gemcitabine/cisplatin vs. gemcitabine/cisplatin alone in advanced biliary tract cancer

19 Apr, 2023 | 13:10h | UTC

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)

News Release: First-line Pembrolizumab Plus Chemotherapy May Benefit Patients with Advanced Biliary Tract Cancers – American Association for Cancer Research

 

Commentary on Twitter

 

RCT | Zolbetuximab plus mFOLFOX6 in CLDN18.2+ HER2- advanced gastric or gastro-oesophageal junction adenocarcinoma

17 Apr, 2023 | 13:00h | UTC

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial – The Lancet (link to abstract – $ for full-text)

News Release: Results from Astellas’ Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet – PR Newswire

 

Cohort Study | Cancer surveillance as an alternative to prophylactic total gastrectomy in hereditary diffuse gastric cancer

17 Apr, 2023 | 12:57h | UTC

Cancer surveillance as an alternative to prophylactic total gastrectomy in hereditary diffuse gastric cancer: a prospective cohort study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Endoscopic Surveillance in Patients at Risk for Hereditary Diffuse Gastric Cancer – The ASCO Post

 

Review | Diagnostic, structured classification and therapeutic approach in cystic pancreatic lesions

12 Apr, 2023 | 12:58h | UTC

Diagnostic, Structured Classification and Therapeutic Approach in Cystic Pancreatic Lesions: Systematic Findings with Regard to the European Guidelines – Diagnostics

Related:

Diagnostic Approach to Incidentally Detected Pancreatic Cystic Lesions – Current Treatment Options in Gastroenterology

Cystic pancreatic lesions: MR imaging findings and management.

Recommendations for the management of incidental pancreatic findings in adults.

Pancreatic cystic neoplasms: a review of current recommendations for surveillance and management

Management of Pancreatic Cystic Lesions

Consensus Recommendations: Diagnosis and Surveillance of Incidental Pancreatic Cystic Lesions

Review: Pancreatic Cystic Lesions

Guidelines on pancreatic cystic neoplasms

 

Screening colonoscopy in seniors: common in patients with limited life expectancy and associated with higher complication risks

11 Apr, 2023 | 14:30h | UTC

Frequency of Use and Outcomes of Colonoscopy in Individuals Older Than 75 Years – JAMA Internal Medicine (link to abstract – $ for full-text)

Related: Study reveals overuse of surveillance colonoscopy in older adults with limited life expectancy

 

Commentary:

 

SR | Risk factors for cholangitis after pancreatoduodenectomy

11 Apr, 2023 | 14:21h | UTC

Risk Factors for Cholangitis After Pancreatoduodenectomy: A Systematic Review – Digestive Diseases and Sciences

 

Cohort Study | Impact of complications after resection of pancreatic cancer on disease recurrence and survival

10 Apr, 2023 | 13:34h | UTC

Impact of complications after resection of pancreatic cancer on disease recurrence and survival, and mediation effect of adjuvant chemotherapy: nationwide, observational cohort study – BJS Open

 

Commentary on Twitter

 

Brief Review | What every gastroenterologist should know about gastrointestinal neuroendocrine tumors

4 Apr, 2023 | 13:29h | UTC

What Every Gastroenterologist Should Know About Gastrointestinal NETs – American Journal of Gastroenterology

 

Cohort Study | Celiac axis stenosis is an underestimated risk factor for increased morbidity after pancreatoduodenectomy

4 Apr, 2023 | 13:20h | UTC

Celiac Axis Stenosis is an Underestimated Risk Factor for Increased Morbidity After Pancreatoduodenectomy – Annals of Surgery

 

Gastric Cancer: the combined impact of H. pylori infection and pathogenic gene variants

3 Apr, 2023 | 13:51h | UTC

Helicobacter pylori, Homologous-Recombination Genes, and Gastric Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Helicobacter Pylori Infection Modifies the Risk of Gastric Cancer Associated with Germline Pathogenic Variants in Homologous Recombination Genes – ESMO

Commentary: H. Pylori Infection Negatively Modifies Genetically Increased Risk for Gastric Cancer – Physician’s Weekly

 

Commentary on Twitter

 

Cohort Study | Long-term quality of life and functional outcome of patients with rectal cancer following a watch-and-wait approach

3 Apr, 2023 | 13:31h | UTC

Long-term Quality of Life and Functional Outcome of Patients With Rectal Cancer Following a Watch-and-Wait Approach – JAMA Surgery (free for a limited period)

Invited Commentary: Guiding Patients Through a “Watch-and-Wait” Approach for Rectal Cancer—Understanding the Functional Outcomes – JAMA Surgery (free for a limited period)

Related:

Cohort Study | A clinical calculator for rectal cancer can estimate recurrence after neoadjuvant therapy with or without surgery.

Guidelines for the surveillance and survivorship care of patients after curative treatment of colon and rectal cancer.

Study: Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy

Study suggests the intensity of active surveillance in patients with rectal cancer managed by a watch-and-wait approach could be reduced if they maintain a complete clinical response within the first 3 years

 

Commentary on Twitter

 

Stay Updated in Your Specialty

No spam, just news.